IPDAnalyticsNewFinal2.png
Subscriber login:
SUBMIT

Remember me

  • Home

  • About IPD

  • Our Solutions

    • US Life-Cycle Insights
    • Global Life-Cycle Insights
    • - Europe
    • - Japan
    • - Canada
    • - Australia
    • - Brazil
    • - Mexico
    • - India
    • - Korea
    • - Russia
    • - China
    • - Taiwan
    • Global Patent Search (GPS)
    • Payer & Provider Insights
    • - Access Hub
    • Market & Financial Insights
    • - Rebate Monitor
    • Coding & Reimbursement
    • Budget Impact
    • Med-Tech Insights
  • Our Subscribers

    • Brand Manufacturers
    • Generic Manufacturers
    • Payers and Managed Care
    • Hospitals and Health Systems
    • Supply Chain Members
    • Institutional Investors
    • Other Industry Stakeholders
  • Podcast

    • Limited Distribution Drugs Part 1 & 2
    • Patient Financial Assistance Programs
    • Drug Pricing and Reimbursement 101
    • Understanding Authorized Generics
    • Manufacturer Life-Cycle Strategies
    • An Inside Look at Formulary Management
    • Provider Strategies for Max Revenue
    • Understanding 505(b)(2)s
    • Skinny Labels and Off-Label Utilization
  • News & Resources

  • Samples

    • Insight Briefs
    • Featured Sample Reports
  • Careers

  • Talk to Us

  • More...

    Use tab to navigate through the menu items.
    • View All
    • News Articles
    • IPD Resources
    Search
    How Will Payers Manage Multiple Adalimumab Biosimilars? Jeffrey Casberg Explains
    • Jun 22
    News Articles

    How Will Payers Manage Multiple Adalimumab Biosimilars? Jeffrey Casberg Explains

    Jeffrey Casberg, vice president of pharmacy at IPD Analytics, discussed the different options that payers have to manage the growing...
    6 Payor Tactics to Control Drug Spending
    • Jun 1
    News Articles

    6 Payor Tactics to Control Drug Spending

    By Karen Blum The growth of high-cost specialty drugs is causing payors to scramble to manage spending on these products, speakers said...
    Data on Adalimumab Biosimilar Confirm Equivalence of Low- and High-Concentration Formulations
    • Jun 1
    News Articles

    Data on Adalimumab Biosimilar Confirm Equivalence of Low- and High-Concentration Formulations

    Research presented at EULAR 2022 demonstrated the pharmacokinetic equivalence of a low-concentration version of the adalimumab biosimilar...
    New Phase Will Increase Trajectory of Biosimilar Use in the United States, Expert Says
    • May 30
    News Articles

    New Phase Will Increase Trajectory of Biosimilar Use in the United States, Expert Says

    With multiple adalimumab biosimilars poised to enter the market and more biosimilars in more disease states seeking interchangeability,...
    Payer Management Tools and Trends for Biosimilars in the US
    • May 26
    News Articles

    Payer Management Tools and Trends for Biosimilars in the US

    As biosimilar competition heats up in the United States, payers have more tools at their disposal to manage these agents. By Laura Joszt...
    Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
    • Apr 12
    News Articles

    Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?

    Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among...
    Upcoming Generics Provide New Considerations and Opportunities for Savings
    • Apr 1
    News Articles

    Upcoming Generics Provide New Considerations and Opportunities for Savings

    In 2022 and 2023, there are a number of big therapies losing patent exclusivity, which opens the door to generics that could save as much...
    Jeffery Casberg Previews His Presentations at AMCP 2022
    • Mar 29
    News Articles

    Jeffery Casberg Previews His Presentations at AMCP 2022

    Jeffrey Casberg, vice president of pharmacy at IPD Analytics, previews his sessions about the new and emerging pharmaceutical products...
    Data, Disparities, Drug Pricing Take Center Stage at AMCP 2022
    • Mar 25
    News Articles

    Data, Disparities, Drug Pricing Take Center Stage at AMCP 2022

    The annual spring meeting of AMCP 2022 will include keynote sessions on health care and marketplace trends and the specialty...
    How Cost-Effective Are New Drugs for Myasthenia Gravis? An ICER Review Weighs the Options
    • Nov 18, 2021
    News Articles

    How Cost-Effective Are New Drugs for Myasthenia Gravis? An ICER Review Weighs the Options

    An ICER review of eculizumab and efgartigimod for Myasthenia Gravis expressed serious concerns about drug pricing.
    IPD Executive Offers Perspective on Biosimilar Uptake and Policy
    • Nov 1, 2021
    News Articles

    IPD Executive Offers Perspective on Biosimilar Uptake and Policy

    Payers have moved from toe-in-the-water biosimilar policies to aggressive management, contributing to robust savings in recent years.
    Pharmacy Policy Experts Describe Changes in Biosimilar Adoption Curve
    • Nov 1, 2021
    News Articles

    Pharmacy Policy Experts Describe Changes in Biosimilar Adoption Curve

    Authorized biologics are on the horizon and their release will likely coincide with the arrival of the first interchangeable biosimilar.
    An Interchangeable Biosimilars vs Authorized Biologics Battle May Be Looming
    • Oct 27, 2021
    News Articles

    An Interchangeable Biosimilars vs Authorized Biologics Battle May Be Looming

    Competitors in the field of adalimumab and insulin products may soon include authorized biologics.
    AMCP Nexus 2021: A Wrap-Up
    • Oct 22, 2021
    News Articles

    AMCP Nexus 2021: A Wrap-Up

    Biosimilar adoption and biosimilar market share were among the featured topics at the AMCP Nexus 2021 meeting in Denver, Colorado.
    AMCP Nexus 2021: Biosimilars Are Gathering Momentum — and Interchangeability May Not Matter
    • Oct 21, 2021
    News Articles

    AMCP Nexus 2021: Biosimilars Are Gathering Momentum — and Interchangeability May Not Matter

    IPD Analytics discussed biosimilar uptake as both biosimilar market share and adoption of biosimilars become more prominent.
    Further Dissecting the Launch of Adalimumab Biosimilars in the US
    • Apr 21, 2021
    News Articles

    Further Dissecting the Launch of Adalimumab Biosimilars in the US

    According to the IPD Analytics team, an adalimumab biosimilar launch may occur as early as late 2022.
    National Trends in Prescription Drug Expenditures and Projections for 2021
    • Apr 21, 2021
    News Articles

    National Trends in Prescription Drug Expenditures and Projections for 2021

    Pharmaceutical expenditure was looked at in this study using IPD Analytics pipeline drug data as a source to predict future potential growth
    EY Announces Howard Krass of IPD Analytics, LLC as Entrepreneur Of The Year® 2020 Winner
    • Oct 8, 2020
    News Articles

    EY Announces Howard Krass of IPD Analytics, LLC as Entrepreneur Of The Year® 2020 Winner

    Ernst and Young announced Howard Krass of IPD Analytics was named an Entrepreneur of the Year® 2020 Florida Award winner.
    Will COVID-19 Clog Generics, Biologics Pipeline?
    • May 15, 2020
    News Articles

    Will COVID-19 Clog Generics, Biologics Pipeline?

    IPD Analytics experts discussed the impact of Covid-19 on the drug pipeline.
    IPD Analytics Experts Discuss Humira's Influence on Biosimilars
    • Apr 29, 2020
    News Articles

    IPD Analytics Experts Discuss Humira's Influence on Biosimilars

    IPD Analytics experts discussed biosimilar competition on MJH Life Sciences News Network
    1
    2
    SquareLogoFinal.jpg
    Asset 211.png
    2020 EOY Regional Award Winner Logo-01.p
    LINKS
    CONTACT & CONNECT
    • Home
    • About IPD
    • Our Solutions
      • US Life-Cycle Insights
      • Global Life-Cycle Insights
      • - Europe
      • - Japan
      • - Canada
      • - Australia
      • - Brazil
      • - Mexico
      • - India
      • - Korea
      • - Russia
      • - China
      • - Taiwan
      • Global Patent Search (GPS)
      • Payer & Provider Insights
      • - Access Hub
      • Market & Financial Insights
      • - Rebate Monitor
      • Coding & Reimbursement
      • Budget Impact
      • Med-Tech Insights
    • Our Subscribers
      • Brand Manufacturers
      • Generic Manufacturers
      • Payers and Managed Care
      • Hospitals and Health Systems
      • Supply Chain Members
      • Institutional Investors
      • Other Industry Stakeholders
    • Podcast
      • Limited Distribution Drugs Part 1 & 2
      • Patient Financial Assistance Programs
      • Drug Pricing and Reimbursement 101
      • Understanding Authorized Generics
      • Manufacturer Life-Cycle Strategies
      • An Inside Look at Formulary Management
      • Provider Strategies for Max Revenue
      • Understanding 505(b)(2)s
      • Skinny Labels and Off-Label Utilization
    • News & Resources
    • Samples
      • Insight Briefs
      • Featured Sample Reports
    • Careers
    • Talk to Us

    Headquarters:

    19950 W Country Club Drive
    7th Floor

    Aventura, FL 33180

    ​

    ​

    Australia

    Brazil

    China

    Germany

    India

    Japan

    Mexico

    Netherlands

    South Korea

    Taiwan

    ​

    info@ipdanalytics.com

    +1 (305) 662-8515

    ​

    ​

    • LinkedIn Social Icon
    • Twitter Social Icon

    © 2022 by IPD Analytics | Privacy Policy

    ​

    OLDIPD-analytics-LOGO.png